As a result of technical improvements, extracorporeal carbon dioxide removal (ECCO2R) now has the potential to play an important role in the management of adults with acute respiratory failure. There is growing interest in the use of ECCO2R for the management of both hypoxaemic and hypercapnic respiratory failure. However, evidence to support its use is scarce and several questions remain about the best way to implement this therapy, which can be associated with serious side-effects. This Review reflects the consensus opinion of an international group of clinician scientists with expertise in managing acute respiratory failure and in using ECCO2R therapies in this setting. We concisely review clinically relevant aspects of ECCO2R, and provide a series of recommendations for clinical practice and future research, covering topics that include the practicalities of ECCO2R delivery, indications for use, and service delivery.
|Number of pages||11|
|Journal||The Lancet Respiratory Medicine|
|Early online date||26 Oct 2018|
|Publication status||Published - Nov 2018|
Bibliographical noteCopyright © 2018 Elsevier Ltd. All rights reserved.
FingerprintDive into the research topics of 'Extracorporeal carbon dioxide removal for lowering the risk of mechanical ventilation: research questions and clinical potential for the future'. Together they form a unique fingerprint.
Understanding mechanisms of, and risk factors for, lung injury in the critically illAuthor: Boyle, A., Dec 2021
Supervisor: O'Kane, C. (Supervisor), McAuley, D. (Supervisor) & McNamee, J. (Supervisor)
Student thesis: Doctoral Thesis › Doctor of Philosophy